BioCentury
ARTICLE | Clinical News

PF-00299804: Interim Phase II data

June 8, 2009 7:00 AM UTC

Interim data from an ongoing, open-label, U.S. Phase II trial in 43 evaluable patients, 45 mg/day PF-00299804 produced 3 partial responses and 26 cases of stable disease for >=6 weeks. Seven patients ...